• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Minerva Neurosciences Inc

    12/23/25 4:52:19 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NERV alert in real time by email
    S-8 1 d84517ds8.htm S-8 S-8

    As filed with the U.S. Securities and Exchange Commission on December 23, 2025

    Registration No. 333-  

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Minerva Neurosciences, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   26-0784194

    (State or other jurisdiction of

    Incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    1500 District Avenue

    Burlington, MA

      01803
    (Address of principal executive offices)   (Zip code)

    Minerva Neurosciences, Inc. Amended and Restated 2013 Equity Incentive Plan

    (Full title of the plan)

     

     

    Remy Luthringer, Ph.D.

    Chief Executive Officer

    1500 District Avenue

    Burlington, MA 01803

    (Name and address of agent for service)

    (617) 600-7373

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Marc Recht

    Ryan Sansom

    Cooley LLP

    500 Boylston Street, 14th Floor

    Boston, MA 02116

    (617) 937-2300

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same benefit plan is effective.

    The Registrant previously registered shares of its Common Stock for issuance under the Plan under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on September  15, 2014 (File No. 333-198753), April  30, 2015 (File No. 333-203738), March  14, 2016 (File No. 333-210147), March  13, 2017 (File No. 333-216637), March  12, 2018 (File No. 333-223593), June  15, 2018 (File No. 333-225672) and August  7, 2020 (File No. 333-242460) (each, a “Prior Registration Statement”). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

     

    1


    PART II

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

    The following documents filed by the Registrant with the Commission and the Prior Registration States are incorporated by reference into this Registration Statement:

     

      •  

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February  25, 2025 and on Form 10-K/A on April  21, 2025 and on Form 10-K/A on April 29, 2025;

     

      •  

    The Registrant’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025 and September  30, 2025, filed with the Commission on May  13, 2025, August  14, 2025, and November 5, 2025, respectively;

     

      •  

    The Registrant’s Current Reports on Form 8-K filed with the Commission on January  13, 2025; March  19, 2025; October  22, 2025; November  19, 2025; and December 22, 2025, to the extent the information in such reports is filed and not furnished;

     

      •  

    The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the fiscal year ended December  31, 2024 from the Registrant’s Definitive Proxy Statement on Schedule 14A filed with the Commission on November 24, 2025, to the extent the information therein is filed and not furnished; and

     

      •  

    The description of the Registrant’s Common Stock, which is contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on June 23, 2014, including any amendment or report filed for the purpose of updating such description, including the description of capital stock contained in the Registrant’s registration statement on Form S-3, filed with the Commission on December 23, 2025.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    ITEM 8. EXHIBITS

     

    Exhibit
    Number

      

    Description

      

    Schedule
    Form

       File
    Number
       Exhibit   

    Filing Date

     4.1    Amended and Restated Certificate of Incorporation of the Registrant.    S-1/A    333-19516    3.1    June 10, 2014
     4.2    Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.    8-K    001-36517    3.1    June 17, 2022
     4.3    Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.    S-3    333-292410    3.3    December 23, 2025
     4.4    Amended and Restated Bylaws of the Registrant.    10-Q    001-36517    3.2    November 4, 2019

     

    2


     4.5   Form of Common Stock Certificate of the Registrant.    S-1/A    333-195169    4.1    June 10, 2014
     5.1*   Opinion of Cooley LLP.            
    23.1*   Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.            
    23.2*   Consent of Cooley LLP (included in Exhibit 5.1).            
    24.1*   Power of Attorney (included on the signature page of this registration statement).            
    99.1   Amended and Restated 2013 Equity Incentive Plan.    8-K    001-36517    10.1    December 22, 2025
    99.2   Form of Restricted Stock Unit Agreement under the Amended and Restated 2013 Equity Incentive Plan of the Registrant.    8-K    001-36517    10.1    December 16, 2016
    99.3   Form of Option Grant Agreement under the Amended and Restated 2013 Equity Incentive Plan of the Registrant.    10-K    001-36517    10.36    March 13, 2017
    107*   Filing Fee Table.            
     
    *

    Filed herewith

     

    3


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Burlington, Commonwealth of Massachusetts, on December 23, 2025.

     

    MINERVA NEUROSCIENCES, INC.
    By:  

    /s/ Remy Luthringer, Ph.D.

      Remy Luthringer, Ph.D.
     

    Chief Executive Officer

    (Principal Executive Officer)

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Remy Luthringer, Geoffrey Race and Frederick Ahlholm, and each of them, as his true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature    Title   Date

    /s/ Remy Luthringer, Ph.D.

    Remy Luthringer, Ph.D.

      

    Chief Executive Officer and Chairman of the Board

    (Principal Executive Officer)

      December 23, 2025

    /s/ Frederick Ahlholm

    Frederick Ahlholm

      

    Chief Financial Officer

    (Principal Financial Officer)

      December 23, 2025

    /s/ Hans Peter Hasler

    Hans Peter Hasler

       Member of the Board of Directors   December 23, 2025

    /s/ David Kupfer, M.D.

    David Kupfer, M.D.

       Member of the Board of Directors   December 23, 2025

    /s/ Fouzia Laghrissi-Thode, M.D.

    Fouzia Laghrissi-Thode, M.D.

       Member of the Board of Directors   December 23, 2025

    /s/ Jan van Heek

    Jan van Heek

       Member of the Board of Directors   December 23, 2025

    /s/ Inderjit Kaul, M.D.

    Inderjit Kaul, M.D.

       Member of the Board of Directors   December 23, 2025
    Get the next $NERV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NERV

    DatePrice TargetRatingAnalyst
    3/4/2022$10.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NERV
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Minerva Neurosciences Inc

    SCHEDULE 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

    2/5/26 2:51:20 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Inc filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Minerva Neurosciences, Inc. (0001598646) (Filer)

    2/3/26 9:00:15 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Minerva Neurosciences Inc

    EFFECT - Minerva Neurosciences, Inc. (0001598646) (Filer)

    1/7/26 12:15:18 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

    BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, February 3, 2026 at 10:30 AM ET featuring Gregory Strauss, PhD (Franklin Professor of Psychology, University of Georgia) and Brian Kirkpatrick, MD, MSPH (Peters Professor of Psychiatry, University of Arkansas for Medical Sciences). They will join the company management team to elaborate on the patient burden of the negative symptoms of schizophrenia, the challenges associated with asses

    1/26/26 7:00:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates

    BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2025 ending September 30, 2025. Business Updates  On October 23, 2025, the Company received $80 million in gross proceeds in a private placement, before deducting fees and other expenses. The financing includes an initial upfront funding of $80 million and up to an additional $80 million in gross proceeds if all Tranche A warrants are exercised, subject to the terms and conditions speci

    11/5/25 7:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Kupfer David

    4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

    12/23/25 4:15:22 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Laghrissi-Thode Fouzia

    4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

    12/23/25 4:15:17 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP, CFO and Secretary Ahlholm Frederick W

    4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

    12/23/25 4:15:15 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Minerva Neurosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Minerva Neurosciences with a rating of Buy and set a new price target of $5.00 from $10.00 previously

    3/4/22 6:14:09 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Leadership Updates

    Live Leadership Updates

    View All

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Announces Promotion of Geoff Race to President

    Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that Geoff Race, current Executive Vice President, Chief Financial Officer and Chief Business Officer of Minerva, has been promoted to President. Minerva's Senior Vice President and Chief Accounting Officer, Frederick Ahlholm, has been promoted to Chief Financial Officer. The appointments are effective immediately. These latest leadership

    10/11/21 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development

    WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced Dr. Jay Saoud's retirement and transition to an advisory role and Dr. Ramana Kuchibhatla's appointment as Senior Vice President and Head of Research & Development, both effective September 16, 2021. Dr. Kuchibhatla will report directly to Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. "I would like to thank Jay for the invaluable skill and leadership which have enabled Minerva to take roluperidone from early stage cl

    9/8/21 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Financials

    Live finance-specific insights

    View All

    Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

    BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter ended March 31, 2023. "The first quarter saw the achievement of a significant milestone for our investigational drug, roluperidone, and for Minerva, as the U.S. Food and Drug Administration (FDA) filed our New Drug Application (NDA) for roluperidone for the treatment of negative symptoms of schizophrenia on April 27, 2023. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of

    5/15/23 7:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

    BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release first quarter 2023 financial results and business updates on Monday, May 15, 2023. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates. The live conference call may be accessed here and on the Company's website under Events and Presentations. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 90 days. About Miner

    5/8/23 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

    BURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2022. Corporate Update "In 2022, we had multiple interactions with the FDA regarding the regulatory path forward for our lead compound, roluperidone. After submitting an NDA for roluperidone to the FDA in August, we received a Refuse to File letter (RTF) in the fall, which was upheld following another meeting with the FDA. We remain committed to developing roluperid

    3/8/23 7:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Minerva Neurosciences Inc

    SC 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

    11/12/24 10:32:12 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Minerva Neurosciences Inc

    SC 13G - Minerva Neurosciences, Inc. (0001598646) (Subject)

    2/9/24 9:28:31 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Minerva Neurosciences Inc (Amendment)

    SC 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

    1/18/24 10:21:16 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care